The GvHD Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in GvHD. Our aim is to enhance knowledge in GvHD, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

The GvHD Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.

cGvHD symposium highlights
5:06
cGvHD symposium highlights
Management of drug related adverse events in patients with steroid refractory GvHD
38:03
Management of drug related adverse events in patients with steroid refractory GvHD
Infection prophylaxis for patients with GvHD
33:09
Infection prophylaxis for patients with GvHD
Future perspectives of ECP for GvHD treatment
9:29
Future perspectives of ECP for GvHD treatment
Symposium | Q&A | How ECP can affect lymphocyte count during and after treatment?
1:58
Symposium | Q&A | How ECP can affect lymphocyte count during and after treatment?
Symposium | Early intervention and use of ECP combinations in cGvHD
14:17
Symposium | Early intervention and use of ECP combinations in cGvHD
Symposium | Q&A | Donor lymphocyte infusion post-transplant, and treatment routes if GvHD develops
2:45
Symposium | Q&A | Donor lymphocyte infusion post-transplant, and treatment routes if GvHD develops
Symposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up
29:14
Symposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up
Symposium | The Long-term burden of chronic GvHD
6:14
Symposium | The Long-term burden of chronic GvHD
Symposium | Q&A | Value and challenges of ECP in pediatric patients
1:50
Symposium | Q&A | Value and challenges of ECP in pediatric patients
Symposium: A brief history of ECP
6:43
Symposium: A brief history of ECP
Symposium | Q&A | Impact of ECP on the GvHD treatment landscape
2:14
Symposium | Q&A | Impact of ECP on the GvHD treatment landscape
Supportive care provision for patients with GvHD
21:34
Supportive care provision for patients with GvHD
GvHD prophylaxis: novel strategies and future directions
24:22
GvHD prophylaxis: novel strategies and future directions
Is the novel JAK/ROCK inhibitor TQ05105 effective for patients with SR and SD cGvHD?
2:00
Is the novel JAK/ROCK inhibitor TQ05105 effective for patients with SR and SD cGvHD?
Is combination ATG + PTCy prophylaxis always preferable to using each agent separately in haplo-HCT?
4:22
Is combination ATG + PTCy prophylaxis always preferable to using each agent separately in haplo-HCT?
What is the latest data from REACH-3 for ruxolitinib treated patients with SR-cGvHD after crossover?
4:07
What is the latest data from REACH-3 for ruxolitinib treated patients with SR-cGvHD after crossover?
Case study | Therapy-refractory chronic GvHD
23:46
Case study | Therapy-refractory chronic GvHD
How to sequence agents for steroid-refractory chronic GvHD
15:02
How to sequence agents for steroid-refractory chronic GvHD
Is vedolizumab effective for preventing lower GI acute GvHD?
13:06
Is vedolizumab effective for preventing lower GI acute GvHD?
Itacitinib and corticosteroids for chronic GvHD
7:37
Itacitinib and corticosteroids for chronic GvHD
Key considerations for the use of ECP in GvHD
39:02
Key considerations for the use of ECP in GvHD
What is extracorporeal photopheresis?
35:09
What is extracorporeal photopheresis?
ECP: Looking to the future
12:11
ECP: Looking to the future
What is the latest update on the GRAVITAS-309 trial?
3:52
What is the latest update on the GRAVITAS-309 trial?
The role of ECP in the management of GvHD
1:58
The role of ECP in the management of GvHD
Does using haplo-HSCT compared with cord blood transplant impact GvHD rates?
3:01
Does using haplo-HSCT compared with cord blood transplant impact GvHD rates?
What is the role of human beta-defensin-2 in modulation of the microbiome and aGvHD?
4:49
What is the role of human beta-defensin-2 in modulation of the microbiome and aGvHD?
How should duration of response be defined?
16:23
How should duration of response be defined?
How should novel agents be used in the current treatment pathways for GvHD?
19:12
How should novel agents be used in the current treatment pathways for GvHD?